Taken together, these results suggested that genetic alteration could not explain the dysregulation of BCAM; instead, low BCAM expression could be associated with a higher frequency of BAP1 mutation in ccRCC. The gene discussed is BAP1; the disease is nonpapillary renal cell carcinoma.